Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2021-03-02

FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for the fixed-dose combination of bisoprolol fumarate and hydrochlorothiazide (Teva). This approval updates the prod…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bisoprolol Fumarate and Hydrochlorothiazide (bisoprolol fumarate and hydrochlorothiazide)

Snippet

SUPPL AP for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)